An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)
This observational study will evaluate the use of Avastin (bevacizumab) and conventional chemotherapy in patients \>/= 70 years of age with previously untreated metastatic colorectal cancer. Data will be collected from each patient from initiation of treatment until disease progression occurs (minimum follow-up 12 months).
Colorectal Cancer
Treatment duration in patients receiving chemotherapy with Avastin as first-line therapy in daily clinical practice, approximately 24 months
Treatment duration in patients receiving chemotherapy alone as first-line therapy in daily clinical practice, approximately 24 months|Safety: Incidence of adverse events/adverse events of special interest, approximately 24 months|Clinical/demographic patient characteristics at baseline, approximately 24 months|Dosage/regimen, approximately 24 months|Correlation between Comprehensive Geriatric Assessment (CGA) scores and initial treatment, approximately 24 months
This observational study will evaluate the use of Avastin (bevacizumab) and conventional chemotherapy in patients \>/= 70 years of age with previously untreated metastatic colorectal cancer. Data will be collected from each patient from initiation of treatment until disease progression occurs (minimum follow-up 12 months).